I think the company had it right keeping them separately trialed. Sure they can save money if new management can combine into one study but it's already cost an extra year waiting on fda. So whatever money we save by combining we could have made by selling treatment in 6 more months
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.